Abstract 163P
Background
ERCC1 and ERCC2 are major enzymes involved in nucleotide excision repair (NER). Single nucleotide polymorphisms (SNPs) affect the mRNA level and stability resulting in an alteration in protein translation. ERCC1/2 SNPs potentially association with survival in various cancers but the data in CCA was limited.
Methods
We did a retrospective review and genomic DNA analysis from FFPE tissue of patients diagnosed locally advanced or metastatic CCA who received palliative chemotherapy. The target SNPs included ERCC1 C19007T, C8092A and ERCC2 C312T, A2251C.
Results
Genomic DNA analysis was done in 64 patients but only 54 patients received platinum-based chemotherapy were use in the survival analysis. The ERCC1 C19007T CT SNP had a trend to have better OS than wild-type (CC), 8.8 vs 6.3 months respectively, the HR was statistically significant in multivariate survival analysis (HR 0.47 (0.23-0.94), p = 0.032). The ERCC1 C8092A both homozygous (AA) and heterozygous (CA) SNPs had shorter OS compare with wild-type (CC), 6.2, 8.0 and 9.5 months respectively, there was a trend to statistically significant between CT and CC group HR 1.83 (0.96-3.51), p = 0.067. These findings also observe in response rate and disease control rate. Conversely, ERCC2 SNPs did not associate with the outcome.
Conclusions
ERCC1 C19007T and ERCC1 C8092A SNPs are associated with the overall survival but not the ERCC2 SNPs in cholangiocarcinoma patients receiving platinum-based chemotherapy. Longer survival is seen in ERCC1 C19007T heterozygous SNP (CT) but shorter in ERCC1 C8092A.
Clinical trial identification
Human Ethics Committee of Khon Kaen University (HE611254).
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients
Presenter: Wataru Goto
Session: Poster display session
Resources:
Abstract
42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis
Presenter: Saber Imani
Session: Poster display session
Resources:
Abstract
43P - A hotspot variants p.H1047R and p.H1047L in p110α/ΔNp63α complex affects structure, function and contributes to susceptibility metastatic breast cancer
Presenter: Zou Linglin
Session: Poster display session
Resources:
Abstract
44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location
Presenter: Hubert Beaumont
Session: Poster display session
Resources:
Abstract
46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics
Presenter: Aditia Romadhoni
Session: Poster display session
Resources:
Abstract
47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer
Presenter: MAYUKO MIKI
Session: Poster display session
Resources:
Abstract
48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis
Presenter: Ahmad Murtadha
Session: Poster display session
Resources:
Abstract
49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
50P - Prognostic factors of recurrence or distant metastasis in elderly breast cancer patients
Presenter: Seungju Lee
Session: Poster display session
Resources:
Abstract